BLADDER CANCER: A FIRST IN FRANCE
DECEMBER 15, 2025 In the spotlight, astatine-211, an alpha-emitting radionuclide with high cytotoxic potential that will enable a major step…
News
Discover our latest news, innovations and advances in alpha-immunotherapy.
📰 Filter:
-
-
CLINICAL ALPHATHERAPY STATUS – NOVEMBER 2025
Atonco Report: Overview of clinical developments in alpha-emitter radiotherapy Atonco publishes its November 2025 report outlining the state of clinical…
-
ATONCO ANNOUNCES THE APPOINTMENT OF DR. ALEXANDRA (GITEAU) PAILLARD AS CHIEF OPERATING OFFICER
Atonco, an innovative company specializing in the development of next-generation radiopharmaceuticals based on astatine-211, today announces the promotion of Alexandra…
-
TOWARDS NEW, MORE TARGETED WAYS OF TREATMENT
Bérénice Robert dans La Search trimestriel n°583 – Octobre-Décembre 2025
-
ATONCO AIMS TO REVOLUTIONIZE BLADDER CANCER TREATMENT
Les Echos – SME-Regions / InnovatorsSeptember 2025 In early 2026, Atonco plans to launch a clinical trial for its drug…
-
FRAMATOME INSTALLS FIRST RADIOISOTOPE PRODUCTION SITE IN NANTES
Les Echos – SME-Regions / InnovatorsBy Emmanuel Guimard – July 4, 2025 The nuclear energy specialist will invest €20 to…
-
TARGETED RADIONUCLIDE THERAPY: A MILLIMETER-PRECISE ORCHESTRATION
Magazine Pharmaceutiques n°328By Julie Wierzbicki – June-July 2025 From the processing of raw materials to patient administration, targeted radionuclide therapy…
-
ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Atonco is proud to announce that the results of preclinical and clinical studies have been published in the journal Cancers…
-
FRAMATOME AND IBA TO PARTNER TO DEVELOP AN ASTATINE-211 CYCLOTRON NETWORK IN EUROPE AND THE USA
Framatome & IBA – Press ReleaseParis, France and Louvain-La-Neuve, Belgium – February 7, 2025 Framatome, an international leader in nuclear…
-
ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY
Atonco and GIP ARRONAX (Saint-Herblain, France) are joining forces to take a new step forward in the implementation of alpha-immunotherapy…
-
ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101™
Atonco, a French biotechnology company, and the University of Michigan today announced a collaboration agreement to conduct a targeted alpha-therapy…
-
ATONCO AND MINERVA IMAGING JOIN FORCES TO TARGET BLADDER CANCER
ATONCO (Saint-Herblain, France) and Minerva Imaging (Oelstykke, Denmark) are pleased to announce a close collaboration to join forces in the…
-
TARGETED ALPHA THERAPY CANDIDATE: RECRUITMENT COMPLETED FOR BLADDER CANCER STUDY
Telix (Melbourne, Australia) and Nantes-based company ATONCO S.A.S. (‘ATONCO’) today announced that the last patient has been treated in a…
-
IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure GMP manufacturing and supply…
-
FIRST PATIENT RECEIVES DOSE IN TARGETED ALPHA THERAPY FEASIBILITY STUDY FOR BLADDER CANCER
Atonco announces that a first patient has been dosed in the Phase I ‘PERTINENCE’ study of TLX250-CDx in patients with…